Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Seer, Inc.NASDAQ: SEER

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $1.53M fell 4.4% year over year, behind the -3.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.

Context

  • Depreciation & amortization amounted to 37.9% of revenue in FY2025, down 6.4 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -4.4% toward the trailing-twelve-month pace of -3.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.53M+1.3% QoQ
Last fiscal yearDec 2025
$6.1M-1.2% YoY
LTMMar 2026
$6.03M-3.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.4%——
1 year-1.2%——
3-year CAGR+1.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
6.1M USD
Year-over-year change
-1.2%
4-year CAGR
+14.4%

Depreciation & Amortization vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.9% is the 10th highest of 19, against a peer median of -7.1%.
  • Depreciation & amortization amounts to 40.1% of revenue for SEER, versus a peer median of 9.9%.
SEER Competitors
Depreciation & Amortization for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$14.4M USD-22.3%+20.4%2.1%
SANASana Biotechnology, Inc.LTM Mar 2026$11.49M USD-33.5%-6.6%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M USD-42.2%-13.8%33645.2%
NKTXNkarta, Inc.LTM Mar 2026$9.23M USD+0.4%+51.6%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$8.34M USD+0.8%+30.7%19.4%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$8.23M USD+1.6%+40.8%7.8%
SEERSeer, Inc.LTM Mar 2026$6.03M USD-3.9%+1.1%40.1%
QSIQuantum-Si incorporatedLTM Mar 2026$4.76M USD+6.9%+19.9%257.1%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$3.3M USD-47.7%+5.3%9.5%
PEPGPepGen Inc.LTM Mar 2026$3.2M USD-40.7%+41.5%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$2.79M USD-10.3%+0.1%9.9%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF+9.7%-3.5%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$1.19M USD+3.5%+8.1%—
PHVSPharvaris N.V.LTM Sep 2026€483K EUR+19.4%+39.9%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$314K USD+2.6%+49.5%—
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$39K USD-31.6%——
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%——
MNOVMediciNova, Inc.LTM Mar 2026-$2.07K USD-109.9%+4.3%0.3%
Peer median (excluding SEER) —-7.1%+14.0%9.9%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.